Skip to main content
Top
Published in: Molecular Diagnosis & Therapy 3/2008

01-05-2008 | Diagnostic Profile

Lucica® MI Urinary Myoinositol Kit

A New Diagnostic Test for Diabetes Mellitus and Glucose Intolerance

Authors: Dr Masaru Yamakoshi, Shoji Kawazu

Published in: Molecular Diagnosis & Therapy | Issue 3/2008

Login to get access

Abstract

• Diabetes mellitus is a growing healthcare problem internationally, and poses a major burden from both a individual and societal perspective.
• Diabetes causes potentially life-threatening complications that are preventable if the disease is detected early and appropriate interventions are put in place. Early detection is therefore imperative for preventing diabetes-related morbidity and mortality.
• Current methods of detection, including the oral glucose tolerance test (OGTT), and measures of fasting plasma glucose, glycated hemoglobin (HbA1c), or glycated albumin, can be time-consuming and uncomfortable for patients.
• Myoinositol can be measured in urine and has been found to be elevated in patients with diabetes and glucose intolerance; it has thus proven useful as a marker for the early detection of these conditions.
• Lucica® MI is a diagnostic kit for the measurement of urinary myoinositol; it is used to detect glucose intolerance and diabetes mellitus at an early stage in disease progression. The test is based on an enzymatic method that uses liquid reagents requiring no preparation. Clinical trial results demonstrate that the test could be used to detect not only diabetes mellitus, but also to distinguish impaired fasting glucose and impaired glucose tolerance from normal glucose tolerance.
Literature
1.
go back to reference Tominaga M, Eguchi H, Manaka H, et al. Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose: the Funagata Diabetes Study. Diabetes Care 1999; 22: 920–4PubMedCrossRef Tominaga M, Eguchi H, Manaka H, et al. Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose: the Funagata Diabetes Study. Diabetes Care 1999; 22: 920–4PubMedCrossRef
2.
go back to reference Nóvoa FJ, Boronat M, Saavedra P, et al. Differences in cardiovascular risk factors, insulin resistance, and insulin secretion in individuals with normal glucose tolerance and in subjects with impaired glucose regulation: the Telde Study. Diabetes Care 2005 Oct; 28(10): 2388–93PubMedCrossRef Nóvoa FJ, Boronat M, Saavedra P, et al. Differences in cardiovascular risk factors, insulin resistance, and insulin secretion in individuals with normal glucose tolerance and in subjects with impaired glucose regulation: the Telde Study. Diabetes Care 2005 Oct; 28(10): 2388–93PubMedCrossRef
3.
go back to reference Oizumi T, Daimon M, Jimbu Y, et al. Impaired glucose tolerance is a risk factor for stroke in a Japanese sample: the Funagata study. Metabolism 2008 Mar; 57(3): 333–8PubMedCrossRef Oizumi T, Daimon M, Jimbu Y, et al. Impaired glucose tolerance is a risk factor for stroke in a Japanese sample: the Funagata study. Metabolism 2008 Mar; 57(3): 333–8PubMedCrossRef
4.
go back to reference Blake DR, Meigs JB, Muller DC, et al. Impaired glucose tolerance, but not impaired fasting glucose, is associated with increased levels of coronary heart disease risk factors: results from the Baltimore Longitudinal Study on Aging. Diabetes 2004 Aug; 53(8): 2095–100PubMedCrossRef Blake DR, Meigs JB, Muller DC, et al. Impaired glucose tolerance, but not impaired fasting glucose, is associated with increased levels of coronary heart disease risk factors: results from the Baltimore Longitudinal Study on Aging. Diabetes 2004 Aug; 53(8): 2095–100PubMedCrossRef
5.
go back to reference Muntner P, He J, Chen J, et al. Prevalence of non-traditional cardiovascular disease risk factors among persons with impaired fasting glucose, impaired glucose tolerance, diabetes, and the metabolic syndrome: analysis of the Third National Health and Nutrition Examination Survey (NHANES III). Ann Epidemiol 2004 Oct; 14(9): 686–95PubMedCrossRef Muntner P, He J, Chen J, et al. Prevalence of non-traditional cardiovascular disease risk factors among persons with impaired fasting glucose, impaired glucose tolerance, diabetes, and the metabolic syndrome: analysis of the Third National Health and Nutrition Examination Survey (NHANES III). Ann Epidemiol 2004 Oct; 14(9): 686–95PubMedCrossRef
6.
go back to reference Lim SC, Tai ES, Tan BY, et al. Cardiovascular risk profile in individuals with borderline glycemia: the effect of the 1997 American Diabetes Association diagnostic criteria and the 1998 World Health Organization Provisional Report. Diabetes Care 2000 Mar; 23(3): 278–82PubMedCrossRef Lim SC, Tai ES, Tan BY, et al. Cardiovascular risk profile in individuals with borderline glycemia: the effect of the 1997 American Diabetes Association diagnostic criteria and the 1998 World Health Organization Provisional Report. Diabetes Care 2000 Mar; 23(3): 278–82PubMedCrossRef
7.
go back to reference Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346(6): 393–403PubMedCrossRef Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346(6): 393–403PubMedCrossRef
8.
go back to reference Engelgau MM, Narayan KM, Herman WH. Screening for type 2 diabetes. Diabetes Care 2000; 23: 1563–80PubMedCrossRef Engelgau MM, Narayan KM, Herman WH. Screening for type 2 diabetes. Diabetes Care 2000; 23: 1563–80PubMedCrossRef
9.
go back to reference Yamakoshi M, Takahashi M, Kouzuma T, et al. Determination of urinary myoinositol concentration by an improved enzymatic cycling method using myoinositol dehydrogenase from Flavobacterium sp. Clin Chim Acta 2003; 328(1–2): 163–71PubMedCrossRef Yamakoshi M, Takahashi M, Kouzuma T, et al. Determination of urinary myoinositol concentration by an improved enzymatic cycling method using myoinositol dehydrogenase from Flavobacterium sp. Clin Chim Acta 2003; 328(1–2): 163–71PubMedCrossRef
10.
go back to reference Yamagata F, Kawazu S, Tominaga M, et al. Determination of urinary myo-inositol at 75g oral glucose tolerance test: comparisons of normal, borderline and diabetic types, and setting of cut-off value by ROC analysis. Jpn J Med Pharm Sci 2004; 52(6): 975–80 Yamagata F, Kawazu S, Tominaga M, et al. Determination of urinary myo-inositol at 75g oral glucose tolerance test: comparisons of normal, borderline and diabetic types, and setting of cut-off value by ROC analysis. Jpn J Med Pharm Sci 2004; 52(6): 975–80
11.
go back to reference Kawazu S, Tominaga M, Yamagata F, et al. Determination of urinary myo-inositol: comparison of glucose intolerance group with normal type. Jpn J Med Pharm Sci 2004; 52(6): 981–7 Kawazu S, Tominaga M, Yamagata F, et al. Determination of urinary myo-inositol: comparison of glucose intolerance group with normal type. Jpn J Med Pharm Sci 2004; 52(6): 981–7
12.
go back to reference Sarashina G, Yamakoshi M, Noritake M, et al. A study of urinary myo-inositol as a sensitive marker of glucose intolerance. Clin Chim Acta 2004; 344(1–2): 181–8PubMedCrossRef Sarashina G, Yamakoshi M, Noritake M, et al. A study of urinary myo-inositol as a sensitive marker of glucose intolerance. Clin Chim Acta 2004; 344(1–2): 181–8PubMedCrossRef
Metadata
Title
Lucica® MI Urinary Myoinositol Kit
A New Diagnostic Test for Diabetes Mellitus and Glucose Intolerance
Authors
Dr Masaru Yamakoshi
Shoji Kawazu
Publication date
01-05-2008
Publisher
Springer International Publishing
Published in
Molecular Diagnosis & Therapy / Issue 3/2008
Print ISSN: 1177-1062
Electronic ISSN: 1179-2000
DOI
https://doi.org/10.1007/BF03256283

Other articles of this Issue 3/2008

Molecular Diagnosis & Therapy 3/2008 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.